LaFleur & Godfrey LLC Increases Position in Hologic, Inc. (NASDAQ:HOLX)

LaFleur & Godfrey LLC boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 130,373 shares of the medical equipment provider’s stock after acquiring an additional 3,655 shares during the period. Hologic accounts for 1.3% of LaFleur & Godfrey LLC’s holdings, making the stock its 28th biggest position. LaFleur & Godfrey LLC owned 0.06% of Hologic worth $9,399,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Wolff Wiese Magana LLC purchased a new position in Hologic during the third quarter valued at approximately $25,000. General Partner Inc. purchased a new stake in Hologic during the 4th quarter worth approximately $26,000. First Horizon Advisors Inc. raised its stake in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 134 shares during the last quarter. Sunbelt Securities Inc. purchased a new position in shares of Hologic in the second quarter worth about $37,000. Finally, Cromwell Holdings LLC boosted its holdings in shares of Hologic by 330.2% during the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 416 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.75% of the stock is owned by corporate insiders.

Hologic Stock Performance

Shares of HOLX stock opened at $69.73 on Monday. Hologic, Inc. has a 52 week low of $68.61 and a 52 week high of $84.67. The firm has a 50 day moving average of $74.84 and a two-hundred day moving average of $78.41. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $15.82 billion, a PE ratio of 20.94, a P/E/G ratio of 2.44 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting the consensus estimate of $1.01. The firm had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. Hologic’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.89 EPS. On average, research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on HOLX. Wolfe Research initiated coverage on shares of Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. BNP Paribas raised Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Mizuho decreased their price target on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Hologic in a research report on Monday, January 13th. Finally, Royal Bank of Canada upped their target price on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Seven analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $88.92.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.